Thymosin Alpha-1

Thymosin alpha-1 is a 28-amino-acid peptide studied in innate and adaptive immune signaling, T-cell function, dendritic-cell activity, infection, oncology adjunct research, and immune dysregulation.

Reported effects include modulation of Toll-like-receptor signaling, dendritic-cell maturation, T-cell differentiation, cytokine production, and immune-cell function.

Meaningful human research internationally, with indication-specific variability.

Level II, Meaningful human investigation

Evidence differs substantially by disease, combination therapy, jurisdiction, and formulation. Findings cannot be generalized across all uses.

Reported tolerability is often favorable in studies, but immunologic effects, interactions, hypersensitivity, and product-quality risks remain relevant.

Not broadly FDA-approved in the United States; approved or used in some other jurisdictions.

Supplied strictly for in-vitro and ex-vivo laboratory research. Not for human or veterinary administration, diagnostic, or therapeutic use. Import and regulatory compliance remain the responsibility of the receiving researcher.

Every Cendrix lot ships with an HPLC purity chromatogram, mass-spectrometry identity confirmation, appearance and reconstitution observations, and endotoxin testing where applicable. Lot certificates are retrievable from the Quality page using the lot number printed on the vial.

External searches link to PubMed, ClinicalTrials.gov, Google Scholar, and FDA records. Cendrix does not endorse interpretations published in third-party sources.